Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 4, 2003, Pages 321-327

  Keyes, Kristan A ^a   Mann, Larry ^a   Cox, Karen ^a   Treadway, Patti ^a   Iversen, Philip ^a   Chen, Yun Fei ^a   Teicher, Beverly A ^b  

^a ELI LILLY AND COMPANY   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Angiogenic growth factors; Luminex methodology; Tumor markers

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER THERAPY; CONTROLLED STUDY; CORRELATION FUNCTION; CULTURE MEDIUM; FEMALE; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PLASMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR VOLUME;

EID: 0037902180     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0572-5     Document Type: Article

References (29)

1. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1:27-3
2. Folkman J (1989) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
3. Teicher BA (ed) (1999) Antiangiogenic agents in cancer therapy. Humana Press, New Jersey
4. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22
5. Senger D, Galli S, Dvorak A, Perruzzi C, Harvey V, Dvorak H (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985
6. Poon RT, Fan S, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207-1225
7. Fuhrmann-Benzakein E, Ma M, Rubbia-Brandt L, Mentha G, Ruefenacht D, Sappino A, Pepper M (2000) Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 85:40-45
8. Oehler MK, Caffier H (2000) Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 20:5109-5112
9. Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96:3712-3718
10. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163:343-347
11. Francis J, Bernal SD, Gazdar AF, Thompson R, Baylin S (1980) L-Dopa decarboxylase activity (DCC): a distinguishing biomarker for the growth of small cell lung cancer (SCCL) in tissue culture. Proc Am Assoc Cancer Res 21:52
12. Gasparini G (2001) Clinical significance of determination of surrogate markers for angiogenesis in breast cancer. Crit Rev Oncol Hematol 37:97-114
13. Sheen-Chen S, Chen H, Sheen C, Eng H, Chen W (2001) Serum levels of transforming growth factor β1 in patients with breast cancer. Arch Surg 136:937-940
14. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R (2000) Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant chemotherapy. J Clin Oncol 18:1423-1431
15. Foekens J, Peters H, Grebenchtchikov M, Look M, Meijer-van Gelder M, Geurts-Moespot A, van der Kwast T, Sweep C, Klijn G (2001) High tumor levels of VEGF predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414
16. Kajaniuk D, Marek B, Swietochowska E, Ostrowska Z, Glogowska-Szelag J, Kos-Kudla B, Ciesielska N, Wieloszyski T (2000) Plasma transforming growth factor β1 in breast cancer patients treated with CMF chemotherapy. J Clin Pharm Ther 25:291-294
17. Chin K, Greenman J, Gardiner E, Kumar H, Topping K, Monson J (2000) Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 11:1425-1431
18. Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, Merkert U, Bruch H, Windhovel U (2001) Vascular endothelial growth factor (VEGF) - a valuable serum tumor marker in patients with colorectal cancer? Eur J Surg Oncol 27:37-42
19. Werther K, Christensen I, Brunner N, Nielsen H, and the Danish RANX05 Colorectal Cancer Study Group (2000) Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. Eur J Surg Oncol 26:657-662
20. Takeda A, Shimada H, Imaseki H, Okazumi S, Natsume T, Suzuki T, Ochiai T (2000) Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep 7:333-338
21. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, Imai Y, Nagashima R, Misawa H, Takeda H, Matsuzawa Y, Kawata S (2001) Circulating transforming growth factor β1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7:1258-1262
22. Slaton J, Inoue K, Perrotte P, El-Naggar A, Swanson D, Fidler I, Dinney C (2001) Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158:735-743
23. Junker U, Haufe C, Nuske K, Rebstock K, Stiener T, Wunderlich H, Junker K, Reinhold D (2000) Elevated plasma TGF-β1 in renal diseases: cause or consequence? Cytokine 12:1084-1091
24. Kido Y (2001) Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med J 48:43-47
25. Han H, Silverman J, Santucci T, Macherey R, dAmato T, Tung M, Weyant R, Landreneau R (2001) Vascular endothelial growth factor expression in stage 1 non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8:72-79
26. Baillie R, Carlile J, Pendleton N, Schor A (2001) Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 54:116-120
27. Abendstein B, Daxenbichler G, Windbichler G, Zeimet A, Geurts A, Sweep F, Marth C (2000) Predictive value of uPA, PAI-1, HER-2, and VEGF in the serum of ovarian cancer patients. Anticancer Res 20:569-572
28. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y (1998) Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 34:2041-2045
29. Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K (2000) Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep 7:841-846